Vaximm Seeks Pharma Partners For T-Cell/Checkpoint Inhibitor Combos
Executive Summary
Dr. Matthias Schroff, the new CEO of privately-held Swiss vaccines company Vaximm AG, talks to Mike Ward, global director of content for Informa Pharma Intelligence, about how the company is differentiating itself in the crowded immuno-oncology development space. Vaximm is also looking for pharma partners with checkpoint inhibitors to advance its oral T-cell immunotherapies.
You may also be interested in...
BIO Notebook, Day 4: Annual Convention Winds Down With Oncology In The Spotlight
Oncology was top of mind for Scrip on the final day of the BIO International Convention in San Diego, including a next-generation cancer drug panel discussion and interviews with novel therapeutic developers. A day earlier, we spoke with Merck & Co about deals related to Keytruda and beyond.
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.